

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau




(43) International Publication Date  
21 October 2004 (21.10.2004)

PCT

(10) International Publication Number  
**WO 2004/089897 A1**

- (51) International Patent Classification<sup>7</sup>: **C07D 209/46**, A61K 31/454, A61P 25/24
- (74) Agent: **KONDO, Rie**; GlaxoSmithKline, 980 Great West Road, Brentford, Middlesex TW8 9GS (GB).
- (21) International Application Number: PCT/EP2004/003678
- (22) International Filing Date: 5 April 2004 (05.04.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 0308025.6 7 April 2003 (07.04.2003) GB
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (for all designated States except US): **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).
- (72) Inventors; and
- (73) Inventors/Applicants (for US only): **BONANOMI, Giorgio** [IT/IT]; GlaxoSmithKline, Via Alessandro Fleming 2, I-37135 Verona (IT). **HAMPRECHT, Dieter** [DE/IT]; GlaxoSmithKline, Via Alessandro Fleming 2, I-37135 Verona (IT). **MICHEL, Fabrizio** [IT/IT]; GlaxoSmithKline, Via Alessandro Fleming 2, I-37135 Verona (IT). **TERRENI, Silvia** [IT/IT]; GlaxoSmithKline, Via Alessandro Fleming 2, I-37135 Verona (IT).
- Published:**  
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMPOUNDS HAVING ACTIVITY AT 5HT<sub>2C</sub> RECEPTOR AND USES THEREOF



(I)

(57) Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed: wherein R<sub>1</sub> is halogen, cyano, C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkyloxy, C1-6alkoxy, C1 6alkylthio, hydroxy, amino, mono or di C1 6alkylamino, an

N-linked 4 to 7 membered heterocyclic group, nitro, haloC1-6alkyl, haloC1-6alkoxy, aryl, -COOR<sub>3</sub>, -COR<sub>4</sub> (wherein R<sub>3</sub> and R<sub>4</sub> are independently hydrogen or C1-6alkyl) or -COR<sub>5</sub> (wherein R<sub>5</sub> is amino, mono or di C1 6alkylamino or an N-linked 4 to 7 membered heterocyclic group); p is 0, 1 or 2 or 3; Q is a 6-membered aromatic group or a 6-membered heteroaromatic group; A is -(CH<sub>2</sub>-CH<sub>2</sub>)-, -(CH=CH)-, or a group -(CHR<sub>7</sub>)- wherein R<sub>7</sub> is hydrogen, halogen, hydroxy, cyano, nitro, C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkyloxy, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy or C1 6alkylthio; R<sub>2</sub> is hydrogen, halogen, hydroxy, cyano, nitro, C1-6alkyl, C1-6alkanoxy, C3-7cycloalkyl, C3-7cycloalkyloxy, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, C1 6alkylthio, amino, mono or di C1 6alkylamino or an N-linked 4 to 7 membered heterocyclic group; X is oxygen, sulfur, -CH<sub>2</sub>- or NR<sub>8</sub> wherein R<sub>8</sub> is hydrogen or C1-6alkyl; Y is a single bond, -CH<sub>2</sub>-, -(CH<sub>2</sub>)<sub>2</sub>- or -CH=CH-; and Z is an optionally substituted N-linked heterocyclic group or a C-linked 4 to 7 membered heterocyclic group containing at least one nitrogen, or Z is -NR<sub>9</sub>R<sub>10</sub> where R<sub>9</sub> and R<sub>10</sub> are independently hydrogen or C1-6alkyl. Methods of preparation and uses thereof in therapy, such as for depression or anxiety, are also disclosed.